LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01937676

Enrollment

1250

Registered

2013-09-09

Start date

2013-09-30

Completion date

Unknown

Last updated

2016-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Organ Failure

Brief summary

The purpose of this study is evaluate if K3, a novel biomarker, sampled at arrival to the emergency department can be used to predict the development of organ failure measured as SOFA score. K3 consists of lactate dehydrogenase, albumin and magnesium combined.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥18 years * Admitted to emergency department, Karlstad Central Hospital, Sweden

Exclusion criteria

* Not in need of venous blood sample

Design outcomes

Primary

Measure	Time frame	Description
Development of multiple organ failure	30 days or complete ICU stay	Measured as SOFA score.

Secondary

Measure	Time frame	Description
Cardiac function	30 days or complete ICU stay	Is it possible to predict cardiac function with the novel biomarker K3, which consists of lactate dehydrogenase, albumin, and magnesium combined?
All cause mortality	30 days after admission to emergency department	—

Countries

Sweden

Outcome results